How GLP-1s actually work.

GLP-1 stands for glucagon-like peptide-1. It is a 30-amino-acid hormone released by L-cells in your small intestine within minutes of eating. Its job in normal physiology is to coordinate the response to food: tell the pancreas to release insulin, tell the brain you’re full, and slow down how fast the stomach empties so glucose enters the bloodstream more gradually.

A GLP-1 receptor agonist is a drug that copies this hormone’s signal — but lasts much longer. Native GLP-1 has a half-life of about two minutes. Modern drugs (semaglutide, tirzepatide, dulaglutide) have been engineered with side chains and structural tweaks that resist enzymatic breakdown, pushing half-life out to days or even a week. That’s why a once-weekly injection works at all.

Drugs in this class don’t introduce a foreign mechanism. They amplify a system your body already has — they keep the fed-state signal turned up, even when you’re between meals.

Patients tend to think of GLP-1 as a single “feel less hungry” switch. The reality is a chain of four distinguishable mechanisms operating at different sites in the body:

These four together produce a meaningful caloric deficit without requiring conscious dietary restriction. STEP-1 trial participants on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks; SURMOUNT-1 participants on tirzepatide 15 mg lost 20.9% — without prescribed exercise or caloric targets, just the medication and routine lifestyle counseling.

GLP-1 is one of two main incretin hormones. The other is GIP (glucose-dependent insulinotropic polypeptide), released by K-cells in the duodenum. Tirzepatide, the molecule in Mounjaro and Zepbound, activates both the GLP-1 and GIP receptors at once.

Why does that help? GIP appears to amplify GLP-1’s effect on appetite centers in the hypothalamus, and it also enhances insulin secretion in a glucose-dependent way that complements GLP-1. The clinical evidence is unambiguous: SURMOUNT-5 (2024), the first head-to-head obesity trial, showed tirzepatide produced about 50% more weight loss than semaglutide at the comparable highest doses — roughly 23% vs. 15% body weight.

The next jump up — glucagon receptor agonism, added to retatrutide — works through a different mechanism entirely. Glucagon raises basal metabolic rate (your body burns more energy at rest) and accelerates lipid mobilization in the liver. Phase 2 retatrutide data published in NEJM showed about 24.2% body weight loss at 48 weeks at the 12 mg dose, with the weight-loss curve still descending — not yet plateaued.

Each receptor pathway controls a partly independent metabolic process. Combining them stacks effects rather than overlapping them, which is why dual and triple agonists keep producing better outcomes than maxing out any single pathway.

Roughly 30–45% of patients experience nausea on a GLP-1, concentrated during dose escalation. The mechanism is the same gastric-emptying delay that produces the satiety effect: food sits in the stomach longer, which feels like fullness when it works for you and feels like nausea when the timing is wrong.

The cleanest predictor of nausea severity is meal composition in the 24–48 hours after a dose. High-fat meals delay gastric emptying further on top of the drug’s effect — that’s why patients describe nausea as worse after a heavy restaurant meal than after the same calories eaten at home. Smaller portions, lower fat, and avoiding alcohol post-injection are the practical mitigations that show up in every trial protocol’s patient guidance.

Nausea generally attenuates over weeks as receptors adapt. By month three, fewer than 10% of patients in long-term trials still report it — though for the patients who don’t adapt, discontinuation is reasonable and common.

The longest published follow-up data on a modern GLP-1 is the SUSTAIN extension and the SELECT cardiovascular outcomes trial — about 4 years of continuous semaglutide use. SELECT (2023) showed semaglutide reduced major cardiovascular events by 20% in adults with established heart disease and BMI ≥27, even without diabetes. That’s a structural finding: the weight loss appears to come with metabolic benefits that persist as long as the drug does.

The honest unknowns: we don’t have decade-plus continuous use data yet. The drugs were approved in 2017 (Ozempic) and 2021 (Wegovy), so the world’s longest GLP-1 user has been on for roughly 8–9 years. Concerns about long-term effects on lean body mass, bone density, and gallbladder health are being tracked, but the early signals are not alarming.

What is unambiguous: weight regain begins within weeks of discontinuation. The STEP-1 extension showed about two-thirds of weight loss returns within a year of stopping semaglutide. The current consensus, including from The Endocrine Society’s 2024 guidance, is that GLP-1 therapy for obesity is chronic — like statins for cholesterol or antihypertensives for blood pressure.

Response varies. In SURMOUNT-1, about 96% of tirzepatide 15 mg participants lost at least 5% body weight, but the spread within that 96% was wide — some participants lost 5–10%, others 30%+. Similar spread holds for semaglutide.

Predictors of strong response:

• Higher starting BMI (more room to lose, more proportional caloric deficit)
• Female sex (consistent ~3–5 percentage-point edge across trials)
• Tolerability of dose escalation (those who reach the top dose lose more)
• No prior GLP-1 exposure

Predictors of weaker response:

• Diabetes (meaningful but smaller weight loss than non-diabetics — ~6% vs. 15% on equivalent doses)
• Inability to tolerate higher doses (titration plateaus at lower steps)
• Concurrent medications that promote weight gain (antipsychotics, certain antidepressants)

If you’ve been on a GLP-1 for six months at the maximum tolerated dose and lost less than 5% of body weight, the clinical pattern is that drug is unlikely to ever produce more. Some patients respond to a different molecule (a tirzepatide trial after a semaglutide non-response, for example) — which is one reason the dual and triple agonists are strategically valuable.